The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta-analysis

European Journal of Clinical Pharmacology

Volumn 51, Issue 5, 1997, Pages 389-393

  Christensen, P M ^a   Gotzsche P C ^b   Brosen K ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

CYP2D6; Debrisoquine; Lung cancer; Meta analysis; Sparteine

Indexed keywords

DEBRISOQUINE; SPARTEINE;

ARTICLE; DRUG METABOLISM; GENETIC POLYMORPHISM; HUMAN; LUNG CANCER; OXIDATION; PRIORITY JOURNAL; RISK FACTOR;

CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; DISEASE SUSCEPTIBILITY; GENOTYPE; HUMANS; LUNG NEOPLASMS; ODDS RATIO; OXIDATION-REDUCTION; PHENOTYPE; POLYMORPHISM, GENETIC; RISK FACTORS; SPARTEINE;

EID: 0031015828     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050219     Document Type: Article

References (39)

1. Doll R, Payne P, Waterhause J (1987) Cancer incidence in five continents. IARC Scientific Publications, 15, 42, 88, Berlin
2. Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 309: 901-911
3. Doll R, Peto R (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66: 1191-1208
4. Nebert DW (1991) Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk. Cancer Cell 3: 93-96
5. Idle JR, Armstrong M, Boddy AV, Boustead C, Cholerton S, Cooper J, Daly AK, Ellis J, Gregory W, Hadidi H, Höfer C, Holt J, Leathart J, McCracken N, Monkman SC, Painter JE, Taber H, Walker D. Yule M (1992) The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics 2: 246-258
6. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ (1991) A tobacco smoke-derived nitrosamine, 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human P4502D6. Carcinogenesis 12: 1197-1201
7. Penman BW, Reece J, Smith T, Yang CS, Gelboin HV, Gonzalez FJ, Crespi CL (1993) Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics 3: 28-39
8. Brøsen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36: 537-547
9. Zanger UM, Vilbois F, Hardwick JP, Meyer UA (1988) Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447-5454
10. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529-532
11. Kalo S, Bowmann ED, Harrington AM, Blomeke B, Shields PG (1995) Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 87: 902-907
12. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controlled Clin Trials 7: 177-188
13. Agúndez JAG, Martinez C, Ladero JM, Ledesma MC. Ramos JM, Martin R, Rodriguez A, Jara C, Benitez J (1994) Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 55: 10-14
14. Benitez J, Ladero JM, Jara C, Carrillo JA, Cobaleda J, Llerena A, Vargas E, Munoz JJ (1991) Polymorphic oxidation of debrisoquine in lung cancer patients. Eur J Cancer 27: 158-161.
15. Caporaso NE, Tucker MA, Hoover RN, Hayes RB, Pickle LW, Issaq HJ, Muchik GM, Gree-Gallo L, Buivys D, Aisner S, Resau JH, Trump BF, Tollrud D, Weston A, Harris CC (1990) Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 82: 1264-1272
16. Duche JC, Barre J, Cremoux Hde, Dalphin JC (1991) Lack of relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br J Clin Pharmacol 31: 533-536
17. Faccini GB, Puchetti V, Zatti N (1990) Dextromethorphan oxidation phenotypes as markers for susceptibility to lung cancer. Clin Chem 36: 387
18. Hirvonen A, Husgafvel Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H (1993) PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 3: 19-27
19. Horsmans Y, Desager JP, Harvengt C (1991) Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility? Biomed Pharmacother 45: 359-362
20. Law MR, Hetzel M, Idle J (1989) Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 59: 686-687
21. Roots I, Drakoulis N, Ploch M, Heinemeyer G, Loddenkemper R, Minks T, Nitz M, Otte F, Koch M (1988) Debrisoquine hydroxylation phenotype, acetylation phenotype. and ABO blood groups as genetic host factors of lung cancer risk. Klin Wochenschr 66: 87-97
22. Shaw GL, Falk RT, Deslauriers J, Frame JN, Nesbitt JC, Pass HI, Issaq HJ, Hoover RN, Tucker MA (1994) Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 4: 41-48
23. Speirs CJ, Murray S, Davies DS, Mabadeje AFB, Boobis AR (1990) Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol 29: 101-109
24. Tefre T, Daly AK, Armstrong M, Leathart JBS, Idle JR, Brøgger A, Børresen A-L (1994) Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 4: 47-57
25. Wolf CR, Smith CA, Gough AC, Moss JE, Vallis KA, Howard G, Carey FJ, Mills K, McNee W, Carmichael J, Spurr NK (1992) Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13: 1035-1038
26. Ayesh R, Idle J, Ritchie JC, Crothers MJ, Hetzel M (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312: 169-170
27. Hetzel MR, Law M, Keal EE, Sloan TP, Idle JR, Smith RL (980) Is there a genetic component in bronchial carcinoma in smokers? Thorax 35: 709
28. Roots I, Brockmoeller J, Drakoulis N, Loddenkemper R (1992) Mutant genes of cytochrome P-4502D6, gluthatione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients. Clin Invest 70: 307-319
29. Roots I, Drakoulis N, Brockmöller J (1993) Still an open question: does active CYP2D6 predispose to lung cancer. 8th Int Conf on Cytochrome P450, Lisbon 159 (abstract)
30. Stucker I, Cosme J, Laurent P, Cenee S, Beaune P, Bignon J, Depierre A, Milleron B, Hemon D (1995) CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis 16: 2759-2764
31. Pocock SJ, Hughes MD, Lee RJ (1987) Statistical problems in the reporting of clinical trials: a survey of three medical journals. N Engl J Med 317: 426-432
32. Fischl MA, Richman DD, Grieco MH. Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, Phil D, King D and the AZT collaborative working group (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind placebo-controlled trial. N Engl J Med 317: 185-191
33. Aboulker J-P, Swart AM (1993) Preliminary analysis of the Concorde trial. Lancet 341: 889-890
34. Wolf CR, Smith CAD, Bishop T, Forman D, Gough AC, Spurr NK (1994) CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics 4: 104-106
35. London SJ, Daly AK, Thomas DC, Caporaso NE, Idle JR (1994) Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer. Pharmacogenetics 4: 107-108
36. Alván G, Bechtel P, Iselius L, Gundert Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533-537
37. Bouchardy C, Benhamou S, Dayer P (1996) The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 56: 251-253
38. Sacks H, Berrier J, Reitman D (1987) Meta-analyses of randomized controlled trials. N Engl J Med 316: 450-455
39. Dickersin K, Berlin JA (1992) Meta-analysis: state-of-the-science. Epidemiol Rev 14: 154-176